Atea Pharmaceuticals, Inc.
AVIR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AVIR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVIR
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies, with lead programs in hepatitis C virus (HCV) and hepatitis E virus (HEV), currently conducting Phase 3 trials for its bemnifosbuvir/ruzavir regimen.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$429.9M
Cash Runway
17.4 moLead Asset
at-587 (Phase 1)
Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 10 clinical trials · 2 catalysts for Atea Pharmaceuticals, Inc..
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies, with lead programs in hepatitis C virus (HCV) and hepatitis E virus (HEV), currently conducting Phase 3 trials for its bemnifosbuvir/ruzavir regimen.
- Lead product candidate is the combination of bemnifosbuvir and ruzasvir for the treatment of HCV, currently in Phase 3 clinical trials [sec_mda · as of 2026-03-05].
- Cash and equivalents of $76.5M as of 2026-06-30, with a net loss of $32.9M for the quarter [sec].
- A workforce reduction of approximately 25% was implemented in 2025, expected to save about $15 million through 2027 [sec_mda · as of 2025-11-12].
- The company is also exploring early-stage candidates for HEV (AT-587) and other RNA viral infections [sec_mda · as of 2026-03-05].
What works
- Atea has a clear late-stage catalyst: Phase 3 topline data for the bemnifosbuvir/ruzavir regimen in HCV is expected in December 2026 and March 2027 [sec_mda · as of 2026-03-05].
- The company has a potential $10.0 million milestone payment upon FDA acceptance of an NDA for a ruzasvir-containing product, anticipated in mid-2027 [sec_mda · as of 2026-03-05].
- Management believes existing resources are sufficient to complete clinical development of the HCV regimen through key inflection points [sec_mda · as of 2025-11-12].
What to weigh
- The company has a history of significant operating losses, with net cash used in operating activities of $132.0 million for the year ended December 31, 2025 [sec_mda · as of 2026-03-05].
- Atea anticipates needing substantial additional capital to fund operations, with no assurance of securing financing on favorable terms [sec_mda · as of 2026-05-12].
- The HCV treatment market is highly competitive, with established generic and branded therapies, posing commercial risk even if the regimen is approved [sec_mda · as of 2026-03-05].
From the filings
Quoted directly from source documents.
Atea is conducting Phase 3 trials for its HCV regimen.
“the ongoing HCV Phase 3 clinical trials evaluating the regimen of bemnifosbuvir and ruzasvir”
SEC MD&A · March 5, 2026
Atea reduced its workforce by 25% to cut costs.
“we reduced our workforce by approximately 25%. This workforce reduction is expected to result in aggregate cost savings of approximately $15 million through 2027.”
SEC MD&A · November 12, 2025
Atea has a potential $10 million milestone tied to FDA NDA acceptance.
“The next potential milestone, in the amount of $10.0 million, is payable upon acceptance by the FDA of a new drug application covering a product candidate including ruzasvir.”
SEC MD&A · March 5, 2026
Atea is exploring early-stage HEV candidate AT-587.
“other drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for other product candidates including AT-587 for the treatment of HEV”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline — Phase 3 Topline: Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvi — Topline data from a Phase 3 trial comparing bemnifosbuvir/ruzavir to standard of care in HCV patients.
- 2027-03-01 · Phase3_Topline — Phase 3 Topline: An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Tr — Topline data from a second Phase 3 trial comparing bemnifosbuvir/ruzavir to sofosbuvir/velpatasvir in HCV.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 3 HCV trials may fail to meet efficacy or safety endpoints, leading to program discontinuation [sec_mda · as of 2026-03-05].
- Capital needs and dilution — Atea may need to raise substantial additional capital, potentially diluting existing shareholders [sec_mda · as of 2026-05-12].
- Competitive market for HCV — The HCV treatment market is crowded with effective generics and branded therapies, limiting commercial potential [sec_mda · as of 2026-03-05].
- Regulatory and manufacturing risks — Delays in FDA acceptance or manufacturing issues could postpone NDA submission and milestone payments [sec_mda · as of 2026-03-05].
What to watch
- Phase 3 topline data for bemnifosbuvir/ruzavir in HCV expected in December 2026 and March 2027 [sec_mda · as of 2026-03-05].
- FDA acceptance of an NDA for a ruzasvir-containing product, which triggers a $10.0 million milestone payment [sec_mda · as of 2026-03-05].
- Cash burn rate and any additional financing or partnership announcements to extend runway beyond current $76.5M [sec].
- Progress of early-stage HEV candidate AT-587 and other preclinical programs [sec_mda · as of 2026-05-12].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Atea Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atea Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
17.4 months
D/E 0.14 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~93d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
125
Total value held
$281.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 11,950,772 | $64.3M |
| blackrock, inc. | 8,435,437 | $45.4M |
| vanguard capital management llc | 6,492,248 | $34.9M |
| tang capital management llc | 4,814,700 | $25.9M |
| two sigma investments, lp | 1,864,164 | $10.0M |
| geode capital management, llc | 1,747,706 | $9.4M |
| state street corp | 1,694,635 | $9.1M |
| dimensional fund advisors lp | 1,255,484 | $6.8M |
| rosalind advisors, inc. | 1,171,855 | $6.3M |
| renaissance technologies llc | 1,166,400 | $6.3M |
Showing top 10 of 125 institutional holders of Atea Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 12.1%
- Days to cover
- 24.4
- Shares short
- 7,488,888
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVIR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Atea Pharmaceuticals, Inc.?
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies, with lead programs in hepatitis C virus (HCV) and hepatitis E virus (HEV), currently conducting Phase 3 trials for its bemnifosbuvir/ruzavir regimen.
What is Atea Pharmaceuticals, Inc.'s lead drug candidate?
Atea Pharmaceuticals, Inc.'s most advanced tracked candidate is at-587 (Phase 1) for Hepatitis E.
What is Atea Pharmaceuticals, Inc.'s next catalyst?
Atea Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvi" — expected December 1, 2026.
Who is the CEO of Atea Pharmaceuticals, Inc.?
Dr. Jean-Pierre Sommadossi Ph.D. is the chief executive officer of Atea Pharmaceuticals, Inc. (AVIR).
Where is Atea Pharmaceuticals, Inc. headquartered?
Atea Pharmaceuticals, Inc. (AVIR) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.